Abstracts Archive - Page 1351 of 2607 - ACR Meeting Abstracts

Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Maria Rydholm^1,2, Ingegerd Wikström^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…
Abstract Number: 2473 • 2018 ACR/ARHP Annual Meeting
The Relation between Inflammatory Joint Activity and Disability Related to the Lower Extremities in Early Rheumatoid Arthritis
Maria Mellblom Bengtsson^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Arthritis in the lower extremities has a major impact in many patients in rheumatoid arthritis (RA), but has not been extensively studied. The objective…
Abstract Number: 2474 • 2018 ACR/ARHP Annual Meeting
Development of a Crosswalk for FACIT-10 (Psychometric Work)
Clifton O. Bingham III¹, Susan J. Bartlett^2,3, David Cella⁴, Amy M. DeLozier⁵, Luna Sun⁵, Amanda Quebe⁵, Susan Otawa⁵ and Carol L. Gaich⁵, ¹Johns Hopkins University, Baltimore, PA, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Northwestern University, Chicago, IL, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Fatigue in patients with rheumatoid arthritis (RA) may be measured with the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue instrument (FACIT-F). The Patient-Reported Outcomes…
Abstract Number: 2475 • 2018 ACR/ARHP Annual Meeting
Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Clifton O. Bingham III¹, Sergio Schwartzman², Shelly Kafka³, Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Jeffrey R. Curtis⁵, ¹Johns Hopkins University, Baltimore, PA, ²Weill Cornell Medical College, New York, NY, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PROMIS (Patient Reported Outcomes Measurement Information System) has been used in rheumatoid arthritis (RA) patients (Pts) to assess disease activity across multiple domains (i.e.…
Abstract Number: 2476 • 2018 ACR/ARHP Annual Meeting
Analysis of the Disease Activity and Functional Measures of Young Patients with Rheumatoid Arthritis Undergoing Total Joint Arthroplasty By Using the Database of Nation-Wide Observational Cohort
Kimio Masuda¹, Tatsuou Ikenaka¹, Toshihiro Matsui² and Shigeto Tohma³, ¹Department of Rehabilitation Medicine, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ²Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ³National Hospital Organization Tokyo National Hospital, Kiyose, Japan
Background/Purpose: The aim of this study was to investigate the impact of total joint arthroplasty (TJA) on the disease activity and functional measures of young…
Abstract Number: 2477 • 2018 ACR/ARHP Annual Meeting
Which Is the Best Measure for Rheumatoid Arthritis Disease Activity? a Head to Head Comparison of the Six American College of Rheumatology Recommended Disease Activity Measures
Mamatha Katikaneni¹, Sunny Patel², Arina Garg², Madiha Tariq², Sebastian Wilk², Khagendra Dahal³, Robert Walter³ and Samina Hayat⁴, ¹Rheumatology, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ²Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ³Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ⁴Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA
Background/Purpose: Treat-to-target is the recommended strategy for the appropriate management of Rheumatoid arthritis (RA) which involves regular assessment and monitoring of disease activity using a…
Abstract Number: 2478 • 2018 ACR/ARHP Annual Meeting
Do Age and Education Influence the Disease Activity Score? an Explorative Analysis in the Norwegian Register of Dmards
Marloes van Onna¹, Polina Putrik¹, Elisabeth Lie², Tore Kvien³, Annelies Boonen¹ and Till Uhlig², ¹Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: While ageing influences auto-immune inflammation and the structure of the joints, knowledge about its influence on appraisal of disease outcomes is more limited. The…
Abstract Number: 2479 • 2018 ACR/ARHP Annual Meeting
Pilot Study of Characterizing Rheumatoid Arthritis Related Morning Stiffness
Nino Mikaberidze¹, Ogonna Nwawka², Michael A. McNamara³, Arlene Hurley⁴, Vivian P. Bykerk⁵ and Dana Orange⁶, ¹Rheumatology, Hospital For Special Surgery, New York, NY, ²Radiology, Hospital For Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴The Rockefeller University, New York, NY, ⁵Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Rockefeller University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) related morning stiffness is a cause of early retirement and disability. We hypothesized that circadian variation in hormones or immune cells…
Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Richard Zogala¹, Karla Criner², Maria A. Lopez-Olivo¹, Natalia Zamora³, Devesh Rai¹, Gregory Pratt⁴, Jude K. A. des Bordes¹, Robin Christensen⁵ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Internal Medicine, Baylor College of Medicine, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark
Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
Abstract Number: 2481 • 2018 ACR/ARHP Annual Meeting
Proposal to Re-Evaluate the Definition of Low Disease Activity in Routine Assesment of Patient Index Data 3 (RAPID3) in Rheumatoid Arthritis Patients
Vivekanand Tiwari¹, Ana Maheshwari², Surjeet Dheer² and Martin J. Bergman³, ¹St John's Hospital, Springfield, IL, ²Mercy Catholic Medical Center, Philadelphia, PA, ³Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: There are multiple instruments to measure rheumatoid arthritis disease activity using various patient, lab or physician parameters. Since the RAPID3 has been published, there…
Abstract Number: 2482 • 2018 ACR/ARHP Annual Meeting
The Use of Any Conventional Synthetic DMARD Is Associated with Better Indexes of the Physical Component Evaluated By 12-Item Short-Form Health Survey : Analysis of a Cohort of RA Patients
Alisson Pugliesi¹, Eduardo de Almeida Macedo², Manoel Barros Bertolo³, Rina Dalva Neubarth Giorgi⁴, Sebastião Radominski⁵, Ivânio Alves Pereira⁶, Maria Fernanda Brandao de Resende Guimarães⁷, Paulo Louzada Junior⁸, Maria de Fátima da Cunha Sauma⁹, Karina Bonfiglioli¹⁰, Claiton Brenol¹¹, Lícia M. H. Mota¹² and Geraldo Castelar Pinheiro¹³, ¹INTERNAL MEDICINE, DISCIPLINE OF RHEUMATOLOGY, University of Campinas (UNICAMP), CAMPINAS, Brazil, ²Internal Medicine, University of Campinas (UNICAMP), Campinas, Brazil, ³University of Campinas (UNICAMP), Campinas, Brazil, ⁴Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ⁵Unversidade Federal do Paraná, Curitiba, Brazil, ⁶Universidade Federal de Santa Catarina, Florianópolis, Brazil, ⁷Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ⁸Universidade de São Paulo - Ribeirão Preto, Ribeirão Preto, Brazil, ⁹Universdade Federal do Pará, Belém, Brazil, ¹⁰Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ¹¹Rua Cabral, 764 – Apto 302, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹²Hospital Universitário de Brasília - UnB, Brasília, Brazil, ¹³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Patients with rheumatoid arthritis (RA) report a reduction in quality of life (QoL) in several aspects when compared to the healthy population. QoL can…
Abstract Number: 2483 • 2018 ACR/ARHP Annual Meeting
Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Andreas Kerschbaumer¹, Bruno Bierbaumer², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Independent, Munich, Germany, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is among the most intensively studied chronic inflammatory musculoskeletal diseases. Over the past two decades numerous new compounds have been tested…
Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Ayako Kubota¹, Toru Suguro¹, Arata Nakajima², Masato Sonobe³ and Kazuaki Tsuchiya¹, ¹Toho University Omori Medical Center, Tokyo, Japan, ²Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ³Toho University Sakura Medical Center, Chiba, Japan
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…
Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting
Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Damemarie Paul¹, Laura McDonald¹, Alexander Marshall², Tammy Curtice³, Melissa Lingohr-Smith⁴, Brandy Menges⁴ and Jay Lin⁴, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Novosys Health, Green Brook, NJ
Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
Abstract Number: 2486 • 2018 ACR/ARHP Annual Meeting
Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry
Jeffrey R. Curtis¹, J. Lynn Palmer², George W. Reed³, Jeffrey Greenberg⁴, Dimitrios A. Pappas⁵, Leslie R Harrold⁶ and Joel Kremer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona Research Foundation, Albany, NY, ³UMass Medical School, Worcester, MA, ⁴Corrona LLC, Waltham, MA, ⁵Columbia University, New York, NY, ⁶University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Despite several randomized controlled trials showing comparable clinical outcomes with triple therapy (Triple; MTX, SSZ, HCQ) versus combination therapy with MTX+TNFi (TNFi Combo), the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].